KRAS and non-small cell lung carcinoma: Therefore, to directly assess whether enhanced glycolysis in AMs disrupts SOCS3 secretion, we utilized a similar but distinct mouse model of NSCLC involving the induction of G12D mutant Kras as previously described (15) (Figure 3A).